When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MKGAY - Merck KGaA's evobrutinib shows durable effect in mid-stage MS study
Merck KGaA ADR
Updated results from a Phase 2 clinical trial evaluating Merck KGaA's (OTCPK:MKGAY) evobrutinib (formerly designated as M2951) in patients with relapsing multiple sclerosis (MS) showed a sustained treatment benefit. The data were presented at the American Academy of Neurology Annual Meeting in Philadelphia and simultaneously published in the New England Journal of Medicine.
More news on: Merck KGaA ADR, Healthcare stocks news,